{"aliases":[{"type":"CodeName","name":"CB7630"},{"type":"CodeName","name":"CB 7630"},{"type":"CodeName","name":"CB-7630"},{"type":"USBrandName","name":"Zytiga"},{"type":"USBrandName","name":"Yonsa"},{"type":"CodeName","name":"BR9004"},{"type":"CodeName","name":"BR9004-1"},{"type":"CASRegistryName","name":"154229-18-2"},{"type":"ChemicalStructureName","name":"17-(3-pyridyl)-5,16-androstadien-3beta-acetate"},{"type":"ChemicalStructureName","name":"androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)-"},{"type":"CodeName","name":"JNJ-212082"}],"definition":{"html":"An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","text":"An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/abirateroneacetate","text":"Abiraterone Acetate"},"nciConceptId":"C68845","nciConceptName":"Abiraterone Acetate","termId":552704,"name":"abiraterone acetate","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"abiraterone-acetate"}